Currently, COPD-marketed therapy leaders include GSK’s Trelegy Ellipta, which is set to grow in sales to $2.16bn by 2033.

Patients with COPD and type 2 diabetes using SGLT2i were much less likely to have ER visits and hospitalizations related to COPD exacerbations.

Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest inflammatory and immunology (I&I) markets, ...

The case was dealt with in the Single Justice Procedure, a secretive fast-track courts system which the government is under ...

GSK plc GSK announced positive data from the phase III ANCHOR-1 and ANCHOR-2 studies, which evaluated its pipeline candidate, ...

The European Commission has become the first regulator worldwide to approve Sanofi and Regeneron’s IL-4 and IL-13 inhibitor ... showed signs of efficacy in COPD in a mid-stage trial that also ...

A number of research tools have been combined to study smokers with a range of COPD severities classified according to the GOLD criteria. Methods: Sixty five subjects (11 healthy smokers, 44 smokers ...

More doctors are ordering bioAffinity Technologies' CyPath Lung test and sales are skyrocketing. A long-term military health ...

((SL Advertiser)) New treatment option for those with chronic obstructive pulmonary disease or COPD. To learn more, go to ...

There are several tests that doctors can use to diagnose and monitor COPD. Let's take a look at what abnormal values for ...

Chronic obstructive pulmonary disease is one of the world’s leading causes of death - more than 300 million live with the ...

The early use of interdisciplinary care services and special end-of-life units can improve the quality of end-of-life care for end-stage COPD patients and their families. Several features of COPD ...